Pharma Five is a registered firm based in India. We specialize in Named Patient Imports, Imported cancer drugs, Imported medicines in india.
Contact Us Pharma Five Door No. 74, Old No. 26, Fagun Mansion, 3rd Floor, Ethiraj Salai, Egmore, Chennai - 600008 +916374297988 info@pharmafive.org
Medicine name : Welireg
Generic name : Belzutifan + Lenvatinib
Manufactured By : Merck & Co., Inc. / Eisai Inc.
Indications : Treatment of adults with advanced renal cell carcinoma (RCC) with a clear cell component (ccRCC) following a PD-1 or PD-L1 inhibitor.
Medicine Description : A targeted combination therapy for adults with advanced clear cell renal cell carcinoma (RCC) following PD-1 or PD-L1 inhibitor treatment. Welireg (Belzutifan) combined with Lenvima (Lenvatinib) works by blocking HIF-2α and tumour growth-related pathways, helping slow cancer progression.
Welireg (Belzutifan) with Lenvima (Lenvatinib) is a targeted combination treatment for adults with advanced renal cell carcinoma (RCC) containing a clear cell component after treatment with a PD-1 or PD-L1 inhibitor.
Belzutifan blocks the HIF-2α protein involved in cancer-cell growth, while lenvatinib blocks multiple tyrosine kinase receptors involved in tumour growth and blood vessel formation.
This combination is prescribed for adults with advanced clear cell renal cell carcinoma following treatment with a PD-1 or PD-L1 inhibitor.
Take Welireg and Lenvima orally once daily at the prescribed doses. Welireg tablets should be swallowed whole, and Lenvima capsules should be taken according to the prescribed instructions.
Common side effects include fatigue, high blood pressure, muscle and joint pain, diarrhoea, nausea, vomiting, decreased appetite, constipation, abdominal pain and skin rash.
Yes. Serious side effects may include anaemia, low oxygen levels, heart dysfunction, severe bleeding, kidney problems and liver complications. Contact your doctor if concerning symptoms occur.
Continue treatment until the cancer progresses or side effects become unacceptable, as determined by your oncologist.
Consult your doctor before consuming alcohol during treatment. Avoid excessive alcohol consumption, particularly if you experience dizziness, fatigue or nausea.
Welireg may cause harm to an unborn baby. Pregnancy should be avoided during treatment, and effective non-hormonal contraception should be used as advised by your doctor.
Welireg and Lenvima may interact with other medicines, including certain prescription drugs and supplements. Inform your doctor about everything you take before starting treatment.
For a missed Welireg dose, take it as soon as possible on the same day and resume the regular schedule the next day. If a missed Lenvima dose cannot be taken within 12 hours, skip it and take the next dose at the usual time. Never double a dose.
Yes. Both Welireg and Lenvima may be taken with or without food. Take them at approximately the same time each day.
Attend regular blood tests and monitor blood pressure, oxygen levels, kidney and liver function. Report breathing difficulties, chest pain, unusual bleeding or severe fatigue promptly.
Store Welireg and Lenvima at room temperature between 20°C and 25°C, with permitted excursions between 15°C and 30°C. Keep both medicines in their original packaging and protect them from moisture.
Pharma Five may assist patients seeking Welireg with Lenvima through pharmaceutical consultancy and medicine import support, subject to applicable regulations and required medical documentation. Pharma Five assists in its procurement.